<div id="readability-page-1"><p>Piper Sandler analyst Jessica Tassan maintained a Buy rating on Omnicell today and set a price target of $63.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Tassan is an analyst with an average return of <span>-6.1%</span> and a 38.60% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Claritev, Hinge Health, Inc. Class A, and CVS Health.</p> <p>In addition to Piper Sandler, Omnicell also received a Buy from Benchmark Co.’s Bill Sutherland in a report issued on December 9. However, on the same day, Bank of America Securities reiterated a Hold rating on Omnicell (NASDAQ: OMCL).</p></div>

OMCL

<p>Piper Sandler analyst Jessica Tassan maintained a Buy rating on Omnicell with a price target of $63.00. Tassan has an average return of -6.1% and a 38.60% success rate. Omnicell also received a Buy rating from Benchmark Co.'s Bill Sutherland, while Bank of America Securities reiterated a Hold rating.</p>

Omnicell (OMCL) Gets a Buy from Piper Sandler